BioCentury
ARTICLE | Company News

Alteris Therapeutics Inc., Duke University Medical Center, Johns Hopkins University deal

February 23, 2004 8:00 AM UTC

Alteris licensed from the universities additional rights to its lead product, ALT-110. The compound is a therapeutic vaccine targeting EGFRvIII, a tumor-specific splice variant of the epidermal gro...